(3-bromo-1-(S)-methyl-2-oxopropyl)carbamic acid benzyl ester | 155149-62-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-bromo-1-(S)-methyl-2-oxopropyl)carbamic acid benzyl ester
• 英文别名: (S)-benzyl 4-bromo-3-oxobutan-2-ylcarbamate；Cbz-alanyl bromomethane；benzyl N-[(2S)-4-bromo-3-oxobutan-2-yl]carbamate
• CAS: 155149-62-5
• 化学式: C₁₂H₁₄BrNO₃
• 分子量: 300.152
• InChiKey: YTCSMFTYZYCVFP-VIFPVBQESA-N

物化性质

• 熔点：
  82-83 °C(Solv: ethyl ether (60-29-7); ligroine (8032-32-4))
• 沸点：
  422.4±35.0 °C(Predicted)
• 密度：
  1.420±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3-bromo-1-(S)-methyl-2-oxopropyl)carbamic acid benzyl ester 在 N-碘代丁二酰亚胺 作用下， 以 乙醇 、 乙腈 为溶剂， 生成 (S)-benzyl 1-(6-fluoro-3-iodoimidazo[1,2-a]pyridin-2-yl)ethylcarbamate
  参考文献：
  名称：

  Discovery, Optimization, and in Vivo Evaluation of Benzimidazole Derivatives AM-8508 and AM-9635 as Potent and Selective PI3Kδ Inhibitors

  摘要：

  Lead optimization efforts resulted in the discovery of two potent, selective, and orally bioavailable PI3K delta inhibitors, 1 (AM-8508) and 2 (AM-9635), with good pharmacokinetic properties. The compounds inhibit B cell receptor (BCR)-mediated AKT phosphorylation (pAKT) in PI3K delta-dependent in vitro cell based assays. These compounds which share a benzimidazole bicycle are effective when administered in vivo at unbound concentrations consistent with their in vitro cell potency as a consequence of improved unbound drug concentration with lower unbound clearance. Furthermore, the compounds demonstrated efficacy in a Keyhole Limpet Hemocyanin (KLH) study in rats, where the blockade of PI3K delta activity by inbibitors 1 and 2 led to effective inhibition of antigen-specific IgG and IgM formation after immunization with KLH.

  DOI：

  10.1021/acs.jmedchem.5b01651
• 作为产物：
  描述：

  苄氧羰基-L-丙氨酸 在 氢溴酸 、 溶剂黄146 、 三乙胺 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 4.5h， 生成 (3-bromo-1-(S)-methyl-2-oxopropyl)carbamic acid benzyl ester
  参考文献：
  名称：

  轻松合成光学活性的咪唑衍生物。

  摘要：

  已经从市售和廉价的N-Cbz氨基酸开始，通过简便的4步反应序列合成了五种光学活性的咪唑衍生物。尽管微波辅助的缩合不能成功，但是据揭示相应的α-溴代酮与甲form乙酸酯在液态氨中的缩合是合成这种咪唑衍生物的有用方法。如此制备的衍生物与组胺在结构上相关。

  DOI：

  10.3390/12051183

文献信息

• Stereocontrolled Synthesis of Erythro N-Protected α-Amino Epoxides and Peptidyl Epoxides.
  作者：Amnon Albeck、Rachel Persky

  DOI：10.1016/s0040-4020(01)80651-7

  日期：1994.1

  N-protected α-amino epoxides of erythro configuration, derived from α-amino acids, were synthesized in a stereoselective manner. The erythro (2S,3S) configu- ration was achieved by the synthetic sequence: amino acid → haloketone → halohydrin → epoxide. A mechanistic explanation for the observed stereoselectivity is presented. This stereoselective synthetic approach was applied to the synthesis of a

  以立体选择性方式合成衍生自α-氨基酸的N-保护的赤型构型的α-氨基环氧化物。所述赤氨基酸→卤代酮→卤代醇环氧→：（2S，3S）configu-配给由合成序列来实现的。给出了对所观察到的立体选择性的机械解释。该立体选择性合成方法被用于合成具有预定的手性环氧化物部分的绝对构型的各种短肽基环氧化物。
• Facile Synthesis of Optically Active Imidazole Derivatives
  作者：Ales Marek、Jiri Kulhanek、Miroslav Ludwig、Filip Bures

  DOI：10.3390/12051183

  日期：——

  Five optically active imidazole derivatives have been synthesized via a facile 4-step reaction sequence starting from commercially available and inexpensive N-Cbz amino acids. While microwave assisted condensation was unsuccessful, the condensation of the corresponding alpha-bromoketones with formamidine acetate in liquid ammonia was revealed to be a useful method for the synthesis of such imidazole

  已经从市售和廉价的N-Cbz氨基酸开始，通过简便的4步反应序列合成了五种光学活性的咪唑衍生物。尽管微波辅助的缩合不能成功，但是据揭示相应的α-溴代酮与甲form乙酸酯在液态氨中的缩合是合成这种咪唑衍生物的有用方法。如此制备的衍生物与组胺在结构上相关。
• HETEROCYCLIC COMPOUNDS AND THEIR USES
  申请人：Cushing Timothy D.

  公开号：US20110245257A1

  公开（公告）日：2011-10-06

  Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

  含有替代双环杂环芳基的化合物及其组合物，用于治疗一般性炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、具有炎症成分的皮肤疾病、慢性炎症性疾病，包括但不限于自身免疫疾病，如系统性红斑狼疮（SLE）、重症肌无力、类风湿关节炎、急性播散性脑脊髓炎、特发性血小板减少性紫癜、多发性硬化、Sjögren综合征和自身免疫性溶血性贫血，以及包括所有形式的过敏反应的过敏症状。本发明还提供了治疗依赖于或与p110δ活性相关的癌症的方法，包括但不限于介导的白血病，如急性髓细胞白血病（AML）、骨髓增生异常综合征（MDS）、骨髓增生性疾病（MPD）、慢性髓细胞白血病（CML）、T细胞急性淋巴细胞白血病（T-ALL）、B细胞急性淋巴细胞白血病（B-ALL）、非霍奇金淋巴瘤（NHL）、B细胞淋巴瘤和实体肿瘤，如乳腺癌。
• Ultrasound mediated synthesis of 2-amino-1,3-selenazoles derived from Fmoc/Boc/Z-α-amino acids
  作者：Haraluru S. Lalithamba、N. Narendra、Shankar A. Naik、Vommina V. Sureshbabu

  DOI：10.3998/ark.5550190.0011.b08

  日期：——

  A simple and efficient one-pot synthesis of Fmoc/Boc/Z-amino acid derived 2-amino-1,3-selenazoles by the condensation of NI±-urethane protected amino acid derived bromomethyl ketones with selenourea under the influence of ultrasound has been described. Insertion of 2-amino-1,3-selenazole moiety in the side chains of Asp and Glu has also been achieved following the similar protocol. © ARKAT USA, Inc

  通过 NI±-氨基甲酸酯保护的氨基酸衍生的溴甲基酮与硒脲在超声作用下缩合，简单有效地一锅法合成 Fmoc/Boc/Z-氨基酸衍生的 2-氨基-1,3-硒唑描述。按照类似的协议，在 Asp 和 Glu 的侧链中插入 2-amino-1,3-selenazole 部分也已实现。© ARKAT USA, Inc.
• Chemical compounds 572
  申请人：Berger Markus

  公开号：US20080214641A1

  公开（公告）日：2008-09-04

  Compounds of formula (I): The present invention relates to novel indazolyl ester or amide derivatives, to pharmaceutical compositions comprising such derivatives, to processes for preparing such novel derivatives and to the use of such derivatives as medicaments

  化合物公式（I）：本发明涉及新型吲唑酯或酰胺衍生物，涉及包含这些衍生物的制药组合物，涉及制备这些新型衍生物的过程，以及将这些衍生物用作药物的用途。